CCI
36
2
APD
45
-2
EQIX
64
5
A
43
-5
AVY
47
-7
AN
50
7
AES
47
-3
BAX
38
-12
VIX
22
-14
AMGN
34
3
CMI
71
2
ADP
54
-4
CMCSA
44
-2
AVGO
54
12
CSCO
64
6
CL
58
2
AIZ
78
2
AMG
77
3
AEP
61
-3
BWA
53
-7
CCI
36
2
APD
45
-2
EQIX
64
5
A
43
-5
AVY
47
-7
AN
50
7
AES
47
-3
BAX
38
-12
VIX
22
-14
AMGN
34
3
CMI
71
2
ADP
54
-4
CMCSA
44
-2
AVGO
54
12
CSCO
64
6
CL
58
2
AIZ
78
2
AMG
77
3
AEP
61
-3
BWA
53
-7
Financhill
Back

Dianthus Therapeutics, Inc. Stock Predictions

14K Investors Got In Earlier. You Still Can.

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Buy
63

DNTH
Dianthus Therapeutics, Inc.

Last Price:
$42.48
Seasonality Move:
57.98%

7 Day Trial

ALL ACCESS PASS

$ 7

Share Price Moved. Momentum Hasn't Slowed.

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

Dianthus Therapeutics, Inc. Stock Forecast

  • Over the next 52 weeks, Dianthus Therapeutics, Inc. has on average historically risen by 27.6% based on the past 7 years of stock performance.
  • Dianthus Therapeutics, Inc. has risen higher in 3 of those 7 years over the subsequent 52-week period, corresponding to a historical accuracy of 42.86%
  • Is Dianthus Therapeutics, Inc. Stock Undervalued?
    The current Dianthus Therapeutics, Inc. [DNTH] share price is $42.44. The Score for DNTH is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.
  • DNTH is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.

Will Dianthus Therapeutics, Inc. Stock Go Up Next Year?

  • Over the next 52 weeks, Dianthus Therapeutics, Inc. has on average historically risen by 27.6% based on the past 7 years of stock performance.

Dianthus Therapeutics, Inc. Stock Rating

Buy
63
Dianthus Therapeutics, Inc. (DNTH) is a Buy

Is Dianthus Therapeutics, Inc. overpriced?

  • Dianthus Therapeutics, Inc. has risen higher in 3 of those 7 years over the subsequent 52-week period, corresponding to a historical accuracy of 42.86%

Dianthus Therapeutics, Inc. Stock Price History

Is DNTH stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and DNTH is experiencing slight buying pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
dianthustx.com

52-Week Data

52-Week High:
45.46
52-Week Low:
13.37

Prediction Charts

Market Cap:
1.8B
Price in USD:
42.44
Volume:
3.6M
Beta:
1.99

Technical Analysis

SMA50:
38.73
SMA100:
33.97
SMA200:
26.69
52-Wk Change:
84.2%

Stock Predictions

  • Is Dianthus Therapeutics, Inc. stock public?
    Yes, Dianthus Therapeutics, Inc. is a publicly traded company.
  • What is the Dianthus Therapeutics, Inc. stock quote today?
    The Dianthus Therapeutics, Inc. stock price is 42.44 USD today.
  • How to buy Dianthus Therapeutics, Inc. stock online?
    You can buy Dianthus Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-2 43.18 42.28 43.84 42.19
Dec-3 42.24 43.97 44.53 42.00
Dec-4 43.72 44.71 45.46 43.28
Dec-5 44.96 44.26 45.08 43.61
Dec-8 44.60 43.60 44.60 42.79
Dec-9 43.53 43.58 44.08 42.70
Dec-10 43.54 43.58 43.98 42.96
Dec-11 43.93 41.63 44.06 41.38
Dec-12 41.64 42.13 43.19 40.98
Dec-15 42.48 41.92 42.90 41.48
Dec-16 41.64 41.40 42.26 40.16
Dec-17 41.51 41.43 42.38 40.77
Dec-18 41.89 41.75 42.86 40.77
Dec-19 41.74 42.44 43.58 41.01

Dianthus Therapeutics, Inc. Earnings

Dianthus Therapeutics, Inc. Earnings Report: Per Share Dianthus Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Dianthus Therapeutics, Inc. Forecast Revenue Growth

Dianthus Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Dianthus Therapeutics, Inc. and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, a decrease this year of $1.47 per share, and a decrease next year of $0.13 per share.

* Dianthus Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.